Hyun-Sook Park

Hyun-Sook Park


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JKJaehi Kim
Jaehi Kim
SLSunray Lee
Sunray Lee
YLYeon Kyung Lee
Yeon Kyung Lee
BSBomi Seong
Bomi Seong
HKHyung-Mo Kim
Hyung-Mo Kim
HPHyun-Sook Park
Hyun-Sook Park
The nanoscale spatiotemporal resolution of single-particle tracking (SPT) renders it a powerful method for exploring single-molecule dynamics in living cells or tissues, despite the disadvantages of using traditional organic fluorescence probes, such as the weak fluorescent signal against the strong cellular autofluorescence background coupled with a fast-photobleaching rate. Quantum dots (QDs), which enable tracking targets in multiple colors, have been proposed as an alternative to traditional organic fluorescence dyes; however, they are not ideally suitable for applying SPT due to their hydrophobicity, cytotoxicity, and blinking problems. This study reports an improved SPT method using silica-coated QD-embedded silica nanoparticles (QD2), which represent brighter fluorescence and are less toxic than single QDs. After treatment of QD2 in 10 μg/mL, the label was retained for 96 h with 83.76% of labeling efficiency, without impaired cell function such as angiogenesis. The improved stability of QD2 facilitates the visualization of in situ endothelial vessel formation without real-time staining. Cells retain QD2 fluorescence signal for 15 days at 4 °C without significant photobleaching, indicating that QD2 has overcome the limitations of SPT enabling long-term intracellular tracking. These results proved that QD2 could be used for SPT as a substitute for traditional organic fluorophores or single quantum dots, with its photostability, biocompatibility, and superior brightness.

6 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DSDong Hoon Suh
Dong Hoon Suh
SLSUNRAY LEE
SUNRAY LEE
HPHyun-Sook Park
Hyun-Sook Park
NPNOHHYUN PARK
NOHHYUN PARK
This study was performed to evaluate the anticancer effects of tolerable doses of metformin with or without medroxyprogesterone (MPA) in endometrial cancer cells. Cell viability, cell invasion, and levels of matrix metallopeptidase (MMP) and transforming growth factor (TGF)-β1 were analyzed using three human endometrial adenocarcinoma cell lines (Ishikawa, KLE, and uterine serous papillary cancer (USPC)) after treatment with different dose combinations of MPA and metformin. Combining metformin (0, 100, 1000 µM) and 10 µM MPA induced significantly decreased cell viability in a time- and dose-dependent manner in Ishikawa cells, but not in KLE and USPC cells. In KLE cells, metformin treatment alone significantly inhibited cell invasion in a dose-dependent manner. The inhibitory effect of metformin was reversed when 10 µM MPA was combined, which was significantly inhibited again after treatment of MMP-2/9 inhibitor and/or TGF-β inhibitor. Changes of MMP-9 and TGF-β1 according to combinations of MPA and metformin were similar to those of invasion in KLE cells. In conclusion, the anticancer effects of tolerable doses of metformin varied according to cell type and combinations with MPA. Anti-invasive effect of metformin in KLE cells was completely reversed by the addition of MPA; this might be associated with MMP-9 and TGF-β1.

13 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SBSeung-Hoon Baek
Seung-Hoon Baek
BSBum Jin Shim
Bum Jin Shim
HWHeejae Won
Heejae Won
SLSunray Lee
Sunray Lee
YLYeon Kyung Lee
Yeon Kyung Lee
SKShin-Yoon Kim
Shin-Yoon Kim
Although mesenchymal stem cells (MSCs) insertion has gained recent attention as a joint-preserving procedure, no study has conducted direct intralesional implantation of human umbilical cord-derived MSCs (hUCMSCs) in patients with ONFH. This is a protocol for a phase 1 clinical trial designed to assess the safety and exploratory efficacy of human umbilical cord-derived osteoblasts (hUC-Os), osteogenic differentiation-induced cells from hUCMSCs, in patients with early-stage ONFH. Nine patients with Association Research Circulation Osseous (ARCO) stage 1 or 2 will be assigned to a low-dose (1 × 107 hUC-O cells, n = 3), medium-dose (2 × 107 cells, n = 3), and high-dose group (4 × 107 cells, n = 3) in the order of their arrival at the facility, and, depending on the occurrence of dose-limiting toxicity, up to 18 patients can be enrolled by applying the 3 + 3 escalation method. We will perform hUC-O (CF-M801) transplantation combined with core decompression and follow-up for 12 weeks according to the study protocol. Safety will be determined through adverse event assessment, laboratory tests including a panel reactive antibody test, vital sign assessment, physical examination, and electrocardiogram. Efficacy will be explored through the change in pain visual analog scale, Harris hip score, Western Ontario and McMaster Universities Osteoarthritis Index, ARCO stage, and also size and location of necrotic lesion according to Japanese Investigation Committee classification before and after the procedure. Joint preservation is important, particularly in younger, active patients with ONFH. Confirmation of the safety and efficacy of hUC-Os will lead to a further strategy to preserve joints for those suffering from ONFH and improve our current knowledge of cell therapy.

1 July 2022 in Journal of Medical Devices
Verified
Journal Article
Closed access
PDF file
JPJeong Yeon Park
Jeong Yeon Park
SLSunray Lee
Sunray Lee
DLDong-Mok Lee
Dong-Mok Lee
JLJienny Lee
Jienny Lee
HPHyun-Sook Park
Hyun-Sook Park
GYGil Sang Yoon
Gil Sang Yoon
With advances in biotechnology, the field of cryopreservation has been continuously developed and improved. Typical cryo-container was designed with minimal flow to avoid possible structural defects in LN2 tank, which has a higher thermal conductivity than vapor nitrogen tank. If cells are placed in typical cryo-container and stored in VN2 tank, cross-contamination can be prevented, but the cell viability after thawing may be reduced. The structure of typical cryo-containers is not optimized for vaporized nitrogen to flow quickly into the container and its circulation well. Therefore, we proposed new cryo-container models that can maintain mechanical strength while optimizing the fluid flow structure, and performed thermal–structural coupled field analysis on cryo-containers. We confirmed the cryo-containers by comparing the equivalent stress distributions formed around through holes and evaluating thermal equilibrium in the cryogenic steady-state through flow analysis. Prototype cryo-containers and typical cryo-containers were placed in VN2 tank for a period of time to observe temperature changes. As a result, the time it takes to reach the temperature equilibrium has been reduced to 55% level compared with the typical cryo-containers. Additionally, C2C12 and hADMSC cells were checked after storage under two temperature conditions (−80 and −196 °C). In both cell, viability, adhesion, and relative cell proliferation were improved by up to 15–20% in new containers compared to typical products. The developed container is expected to maintain stability well by being applied to storage and transportation of advanced medicines that require cryopreservation.

2 April 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDong Hoon Suh
Dong Hoon Suh
SLSUNRAY LEE
SUNRAY LEE
HPHyun-Sook Park
Hyun-Sook Park
NPNOHHYUN PARK
NOHHYUN PARK
This study was performed to evaluate the anticancer effects of tolerable doses of metformin with or without medroxyprogesterone (MPA) in endometrial cancer cells. Cell viability, cell invasion, and levels of matrix metallopeptidase (MMP) and transforming growth factor (TGF)-β1 were analyzed using three human endometrial adenocarcinoma cell lines (Ishikawa, KLE, and USPC) after treatment with different dose combinations of MPA (0, 10 μM) and metformin (0, 100, 1000 μM). Combining metformin (0, 100, 1000 μM) and 10 μM MPA induced significantly decreased cell viability in a time- and dose-dependent manner in Ishikawa cells, but not in KLE and USPC cells. There was no dose- or time-dependent cell growth inhibition, or positive western blot results for the expression of progesterone receptors and phospho-AMPKa, following treatment with any combination of metformin (0, 100, 1000 μM) and 10 μM MPA in KLE and USPC cells. In KLE cells, metformin treatment alone significantly inhibited cell invasion in a dose-dependent manner (1.31±0.05, 0.94±0.04, 0.83±0.05 at 0, 100 μM, 1000 μM, respectively; p<0.0005). The inhibitory effect of metformin was reversed to create a stimulating effect when metformin was combined with 10 μM MPA (1.10±0.05, 1.42±0.18, 1.41±0.26 at 0, 100, 1000 μM, respectively; p<0.005). MMP-9 and TGF-β1 showed similar trends in terms of cell invasion in KLE cells. In conclusion, the anti-invasive effect of metformin in KLE cells was completely reversed to the state of no treatment by the addition of MPA; this might be mediated through MMP-9 and TGF-β1. Our study suggests the possibility of these combinations doing harm, rather than good, under some conditions.